Sann.S
SANN.S is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases.
Business. SANN.S is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SANN.S is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of cancer and other serious diseases.
SANN.S has a negative equity position of CHF -11.82 million and a debt-to-equity ratio of -1.37, indicating a leveraged capital structure with liabilities exceeding equity. The company holds CHF 22.44 million in cash and equivalents, which may provide some short-term liquidity, but its operating cash flow is negative at CHF -34.76 million, suggesting ongoing cash burn. The company's liquidity risk is assessed as low, with no immediate filing-based liquidity flags detected.
In terms of profitability, SANN.S reported revenue of CHF 77.19 million, but its operating cash flow is negative, indicating that the company is not generating sufficient cash from operations to sustain its activities. The company's financial performance is below the typical metrics for the biotechnology industry, which often includes high R&D expenses and long development cycles before revenue generation.
SANN.S operates as a single business segment, and its geographic exposure is not disclosed in the available data. The company's revenue concentration is not specified, but as a biotechnology firm, it may be subject to high concentration risk in terms of product lines and geographic markets.
The company's growth trajectory is uncertain, as its revenue and operating cash flow are negative. Analysts have provided a mean price target of CHF 30.00, with a single "buy" recommendation and no "strong buy" ratings, indicating a cautious outlook. The company's capital expenditure is minimal at CHF -52,000, suggesting limited investment in new facilities or equipment.
SANN.S has no immediate filing-based dilution flags, and its dilution risk is assessed as low. The company has not issued new shares recently, and there is no indication of near-term pressure to raise additional capital through equity issuance.
Recent events for SANN.S include the latest financial reporting, which shows a continued reliance on cash reserves to fund operations. No significant regulatory or legal events were disclosed in the available data.
- SANN.S has a negative equity position and is burning cash, indicating a high reliance on external financing.
- The company's liquidity is low, with a negative operating cash flow and a debt-to-equity ratio of -1.37.
- Analysts have a cautious outlook, with a mean price target of CHF 30.00 and only one "buy" recommendation.
- SANN.S has no immediate dilution risk, but its financial position suggests potential future capital needs.
- The company's growth trajectory is uncertain, with no clear signs of revenue expansion or improved cash flow.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,09 |
| Revenue | —no estimate | —no estimate | 104,3M CHF |
| Operating income | —no estimate | —no estimate | 7,3M CHF |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- SANN.S Market data — financials · 2026-05-29
- Santhera Pharmaceuticals Holding AG Market data — analyst estimates · 2026-05-29